Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2

Erb-b2 receptor tyrosine kinase 2 (ErbB2) is an oncogene that frequently overexpressed in a subset of cancers. Anti-ErbB2 therapies have been developed to treat these types of cancers. However, less is known about how anti-ErbB2 drugs affect the trafficking and degradation of ErbB2. We demonstrate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Chinmoy, Xing, Yanli, Cai, Jinyang, Sun, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941056/
https://www.ncbi.nlm.nih.gov/pubmed/36824069
http://dx.doi.org/10.1016/j.bbrep.2023.101436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941056/
https://www.ncbi.nlm.nih.gov/pubmed/36824069
http://dx.doi.org/10.1016/j.bbrep.2023.101436

Ejemplares similares